Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE:002294)
China · Delayed Price · Currency is CNY 32.90
+2.75 (9.12%)
Jun 29, 2026, 3:04 PM CST
SHE:002294 Revenue
Shenzhen Salubris Pharmaceuticals had revenue of 1.23B CNY in the quarter ending March 31, 2026, with 15.65% growth. This brings the company's revenue in the last twelve months to 4.52B, up 13.44% year-over-year. In the year 2025, Shenzhen Salubris Pharmaceuticals had annual revenue of 4.35B with 8.48% growth.
Revenue (ttm)
4.52B
Revenue Growth
+13.44%
P/S Ratio
8.12
Revenue / Employee
1.11M
Employees
4,087
Market Cap
36.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.35B | 340.43M | 8.48% |
| Dec 31, 2024 | 4.01B | 646.89M | 19.22% |
| Dec 31, 2023 | 3.37B | -116.67M | -3.35% |
| Jan 1, 2023 | 3.48B | 423.62M | 13.85% |
| Jan 1, 2022 | 3.06B | 319.83M | 11.68% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Huadong Medicine | 44.06B |
| China Resources Sanjiu Medical & Pharmaceutical | 32.88B |
| Humanwell Healthcare (Group) | 23.93B |
| Beijing Tongrentang | 16.64B |
| Changchun High-Tech Industry (Group) | 11.67B |
| Shijiazhuang Yiling Pharmaceutical | 7.91B |
| Dong-E-E-Jiao | 6.80B |
| Hubei Jumpcan Pharmaceutical | 5.90B |
Shenzhen Salubris Pharmaceuticals News
- 2 months ago - Shenzhen Salubris Pharmaceuticals Annual report: Q4 2025 - Filings
- 2 months ago - Shenzhen Salubris Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 8 months ago - Shenzhen Salubris Pharmaceuticals Quarterly report: Q3 2025 - Filings
- 11 months ago - Shenzhen Salubris Pharmaceuticals Quarterly report: Q2 2025 - Filings